Tempus AI

Tempus AI reported its first net profit in Q2 2026 of $5.6 million, with revenue rising 22% to $382.5 million. Due to strong demand in oncology, management raised the annual guidance to as much as $1.605 billion. The company continues to partner with major pharma firms like AstraZeneca and remains focused on AI-powered diagnostics. » Más en finanzen.net

Andrew Polovin, Tempus AI's EVP and chief legal officer, sold 30,075 shares for about $1.5 million in a non‑discretionary sell‑to‑cover transaction executed under a Rule 10b5‑1 plan. The sale leaves Polovin with 138,140 shares and does not reflect a change in his view on the company. Tempus's shares surged ~75% recently after a Moderna‑Merck cancer vaccine trial validated sequencing technology tied to Tempus's pending Personalis deal, while the company reported 22% revenue growth to $382.5 million and its first GAAP profit last quarter, prompting debate whether the rally already prices in future trial readouts. » Más en finance.yahoo.com

Director Nadja West sold 3,000 Class A shares on August 14 under a Rule 10b5-1 plan she established in May, leaving her with 34,981 shares and keeping significant exposure to Tempus AI. The sale preceded a 24% stock jump driven by positive news around a cancer vaccine and heightened interest in Tempus's pending $1.5 billion Personalis acquisition. Tempus reported a strong Q2 with revenue up 22% and its first GAAP profit, while trailing twelve‑month revenue was $1.4 billion despite a net loss, making operational execution and the Personalis deal the key drivers for investors going forward. » Más en finance.yahoo.com